RxSight, Inc. (RXST) Form 8-K — Nov 3, 2026
RxSight reported Q3 2026 revenue of $24.6 million, down 19% year over year, on 23,128 Light Adjustable Lens units, citing ongoing competitive pressures. Net loss widened to $16.2 million, or $(0.39) per share, from $9.8 million, or $(0.24) per share, a year earlier, with adjusted net loss of $(8.6) million, or $(0.21) per share, versus $(0.04) last year. Gross margin compressed to 73.6% from 79.9% due to higher inventory reserves and costs for LAL and LDD. The balance sheet remains strong with $254.7 million in cash and short-term investments, including $60 million received in the quarter under the Alcon collaboration, though a new $50 million refund liability appeared on the balance sheet.
Key figures
- Revenue
- 24600000
- Revenue Yoy
- -19%
- Total Assets
- 340418000
- Cash Position
- 254700000
- Lal units sold
- 23128
- Gross margin pct
- 73.6% vs 79.9% prior year
- Prior year revenue
- 30340000
- Shares outstanding
- 41927222
- Refund liability current
- 50000000
- Total costs and expenses
- 43104000
- Alcon collaboration payment received
- 60000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.